December 10, 2012 4:09 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Ligand Pharma (NASDAQ: LGND) announced today that it hasinitiated a pivotal trial of Captisol-enabled^®, propylene glycol-free(PG-free) high-dose melphalan as a conditioning treatment prior to autologoustransplant for patients with multiple myeloma. This multi-center trial willevaluate safety and efficacy in 60 patients, and is intended to confirm theresults from an earlier Phase 2 study demonstrating that the PG-free melphalanintravenous formulation was safe and well-tolerated, and met the requirementsfor establishment of bioequivalence to the current commercial intravenousformulation of melphalan (sold by GlaxoSmithKline as Alkeran^® for Injection).Given the robust dataset compiled to date along with the pivotal study design,Ligand believes that should this pivotal trial produce positive results, theCompany will be in a position to submit a 505(b)(2) New Drug Application tothe U.S. Food and Drug Administration.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.